Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma-Reference-Cited by-同舟云学术

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Published:2019-02-11 Issue:3 Volume:25 Page:477-486
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Cloughesy Timothy F.^ORCID,Mochizuki Aaron Y.^ORCID,Orpilla Joey R.^ORCID,Hugo Willy^ORCID,Lee Alexander H.^ORCID,Davidson Tom B.,Wang Anthony C.,Ellingson Benjamin M.,Rytlewski Julie A.^ORCID,Sanders Catherine M.,Kawaguchi Eric S.,Du Lin,Li Gang,Yong William H.,Gaffey Sarah C.,Cohen Adam L.^ORCID,Mellinghoff Ingo K.,Lee Eudocia Q.,Reardon David A.,O’Brien Barbara J.,Butowski Nicholas A.,Nghiemphu Phioanh L.,Clarke Jennifer L.,Arrillaga-Romany Isabel C.,Colman Howard,Kaley Thomas J.,de Groot John F.,Liau Linda M.,Wen Patrick Y.,Prins Robert M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0337-7.pdf

Reference73 articles.

1. Ostrom, Q. T. et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro. Oncol. 19, v1–v88 (2017).

2. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).

3. Lamborn, K. R. et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro. Oncol. 10, 162–170 (2008).

4. Wu, W. et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro. Oncol. 12, 164–172 (2010).

5. Clarke, J. L. et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro. Oncol. 13, 1118–1124 (2011).

Cited by 984 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GBM immunotherapy: Exploring molecular and clinical frontiers;Life Sciences;2024-11

2. Perspective Chapter: Targeting the Myeloid Compartment – Innovative Immunotherapy Strategies for Malignant Brain Tumors;Advanced Concepts and Strategies in Central Nervous System Tumors [Working Title];2024-09-13

3. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape;Frontiers in Immunology;2024-09-13

4. Advances in the treatment of IDH-mutant gliomas;Current Opinion in Neurology;2024-09-12

5. A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma;Radiation Oncology;2024-09-12